Trials / Completed
CompletedNCT02022306
TD-6450 SAD and MAD in Healthy Subjects
A Double-Blinded, Randomized, Placebo-Controlled, Single Ascending Dose (SAD) and Multiple Ascending Dose (MAD) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Food Effect of TD-6450, a NS5A Inhibitor, in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 111 (actual)
- Sponsor
- Theravance Biopharma · Industry
- Sex
- All
- Age
- 18 Years – 60 Years
- Healthy volunteers
- Accepted
Summary
This study consists of two parts, Parts A and B. Part A is a single ascending dose (SAD) study in healthy subjects. Part B is a multiple ascending dose (MAD) study in healthy subjects.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | TD-6450 | |
| DRUG | Placebo |
Timeline
- Start date
- 2014-02-01
- Primary completion
- 2014-08-01
- Completion
- 2014-09-01
- First posted
- 2013-12-27
- Last updated
- 2021-01-14
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02022306. Inclusion in this directory is not an endorsement.